This company has been marked as potentially delisted and may not be actively trading. NYSE:PKI Revvity (PKI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Revvity Stock (NYSE:PKI) 30 days 90 days 365 days Advanced Chart Get Revvity alerts:Sign Up Key Stats Today's Range N/A50-Day Range$115.24▼$137.1152-Week Range N/AVolume1.63 million shsAverage Volume851,117 shsMarket Capitalization$14.57 billionP/E Ratio15.01Dividend Yield0.24%Price TargetN/AConsensus RatingN/A Company OverviewRevvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.Read More… Receive PKI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter. Email Address PKI Stock News HeadlinesRevvity Ramps Up R&D Spending Since PerkinElmer SplitOctober 15, 2024 | msn.comRevvity, Inc. (RVTY)July 19, 2024 | finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.April 18, 2025 | Paradigm Press (Ad)Revvity Inc PKIFebruary 13, 2024 | morningstar.comRevvity Launches EONIS Q System Enabling Faster, Simplified Newborn Screening for SMA and SCIDDecember 1, 2023 | businesswire.comRevvity Stock (NYSE:RVTY), Analyst Ratings, Price Targets, PredictionsNovember 1, 2023 | benzinga.comRevvity, Inc. and Element Biosciences, Inc. Pioneer Next-Generation Sequencing Kits Market with Innovative Genomic Analysis SolutionsOctober 29, 2023 | finance.yahoo.comRevvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS ViewAugust 2, 2023 | finance.yahoo.comSee More Headlines PKI Stock Analysis - Frequently Asked Questions How were Revvity's earnings last quarter? Revvity, Inc. (NYSE:PKI) released its quarterly earnings results on Thursday, May, 11th. The medical research company reported $1.01 EPS for the quarter, missing the consensus estimate of $1.07 by $0.06. The medical research company had revenue of $674.87 million for the quarter, compared to analyst estimates of $686.30 million. Revvity had a net margin of 28.94% and a trailing twelve-month return on equity of 11.17%. Is Revvity doing a stock buyback? Revvity's board initiated a stock repurchase program on Thursday, May 11th 2023, which authorizes the company to repurchase $600,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 4.1% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's leadership believes its shares are undervalued. Does Revvity have any subsidiaries? The following companies are subsidiaries of Revvity: BioLegend, Immunodiagnostic Systems, Nexcelom Bioscience, SIRION Biotech, Oxford Immunotec, Horizon Discovery, Cisbio.com, and others. What other stocks do shareholders of Revvity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Visa (V), Home Depot (HD) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/11/2023Today4/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:PKI CIK31791 Webwww.perkinelmer.com Phone(781) 663-6900Fax781-663-5985Employees16,700Year Founded1937Profitability EPS (Most Recent Fiscal Year)$7.68 Trailing P/E Ratio15.01 Forward P/E RatioN/A P/E Growth0.5Net Income$569.18 million Net Margins28.94% Pretax Margin13.81% Return on Equity11.17% Return on Assets5.83% Debt Debt-to-Equity Ratio0.48 Current Ratio2.43 Quick Ratio2.15 Sales & Book Value Annual Sales$3.31 billion Price / Sales0.00 Cash FlowN/A Price / Cash Flow9.88 Book Value$58.49 per share Price / BookN/AMiscellaneous Outstanding Shares126,410,000Free Float125,755,000Market Cap$14.57 billion OptionableOptionable Beta1.10 Social Links 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NYSE:PKI) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revvity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revvity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.